BioCardia Jumps After FDA Feedback Seen Positive for CardiAMP Approval
BioCardia Inc. shares surged over 50% in busy trading Friday. The move followed an announcement that the company received FDA meeting minutes that could allow its ongoing CardiAMP HF II trial to back a marketing application for its heart-failure cell therapy. The stock traded at $1.40, up 48 cents, with volume above 117 million shares. It earlier hit an intraday high of $1.78. The gain came as the SPDR S&P Biotech ETF dropped about 1.2%, and the iShares Nasdaq Biotechnology ETF also fell.
